The pharmaceutical contract manufacturing market is expected to grow at a CAGR of 6.0% in the first half of the forecast period. The API Manufacturing submarket held 66% of the market in 2017. The key player estimated that the pharmaceutical contract manufacturing market will reach $93bn in 2022.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 230-page report you will receive 77 tables and 58 figures– all unavailable elsewhere.

The 230-page report provides clear detailed insight into the pharmaceutical contract manufacturing market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

• Global Pharmaceutical Contract Manufacturing Market forecasts from 2018-2028

• Submarket forecasts at world level, from 2018-2028:
Active pharmaceutical ingredients (APIs), with sub forecasts for generic APIs, high potency active pharma ingredients (HPAPIs) and other products
Finished dosage formulations (FDFs), with sub forecasts for solid dose forms, injectable dosages and other dosage types
Other applications of outsourced production – other related services

• Revenue forecasts from 2018-2028, for these regional and national markets:
• The US
• Canada
• Japan
• EU5: Germany, France, the UK, Italy and Spain
• BRIC: Brazil, Russia, India, China
• South Korea
• Turkey
• Mexico
• Others

• Assessment of selected leading companies that hold major market shares in the pharmaceutical contract manufacturing industry

• Qualitative Analysis from a CMO Perspective

• Qualitative Analysis from a Client Perspective

This study is intended for anyone requiring commercial analyses for the pharmaceutical contract manufacturing market. You find data, trends and predictions.